Fig 1.
Cost comparison model of empirical versus pre-emptive antifungal therapy in high-risk neutropenic patients.
Fig 2.
PRISMA Flow Diagram of studies included in systematic review and meta-analysis.
Table 1.
Summary of studies comparing empirical versus pre-emptive antifungal therapy in high-risk febrile neutropenic patients.
Table 2.
Comparison of IFD-related outcomes in empiric versus pre-emptive antifungal therapy in high-risk neutropenic patients.
Table 3.
Comparison of antifungal use in empiric versus pre-emptive antifungal therapy in high-risk neutropenic patients.
Fig 3.
Risk of bias in randomized studies as assessed by the Cochrane Collaboration’s “Risk of Bias” tool.
Fig 4.
Risk of bias in non-randomized studies as assessed by the Newcastle-Ottawa Scale.
Fig 5.
Forest plot of pooled relative risk of IFD detection comparing pre-emptive to empirical strategies.
Fig 6.
Forest plot of pooled relative risk of IFD-associated mortality comparing pre-emptive to empirical strategies.
Fig 7.
Forest plot of pooled relative risk of overall mortality comparing pre-emptive to empirical strategies.
Fig 8.
Forest plot of pooled relative risk of antifungal drug use comparing pre-emptive to empirical strategies.
Table 4.
Clinical parameters incorporated into cost comparison model.
Table 5.
Cost parameters incorporated into cost comparison model.
Table 6.
Results of the cost-comparison modela.